ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/head-and-neck-and-neurological
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Head & neck and Neurological
38
trial(s) found.
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06806852
Advanced
Phase 1
Recruiting
A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (
1501-0002
)
anti-EGFR monoclonal antibody
anti-PD-1 monoclonal antibody
anti-SIRPa monoclonal antibody
Head and neck squamous cell carcinoma
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NCT06789172
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (
INVOKE
)
anti-PD-1 monoclonal antibody
prostaglandin EP2/EP4/DP1 receptor inhibitor
Colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Sarcoma
Solid tumour
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
WA
6009 - Nedlands - Linear Clinical Research
NCT06788990
Advanced
Phase 2 / Phase 3
Recruiting
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (
FORTIFI-HN01
)
anti-PD-1 monoclonal antibody
bifunctional EGFR/TGF-beta fusion protein
placebo
Head and neck squamous cell carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
NCT06727565
Advanced
Phase 2
Recruiting
A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma (
VELOCITY-HNSCC
)
Carboplatin
Domvanalimab
Paclitaxel
Zimberelimab
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
platinum-based antineoplastic agent
taxane
Head and neck squamous cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06578871
Radonc
Phase 2
Not yet recruiting
Surgery for the Unknown Primary in the Era of p16-positive Oropharyngeal Squamous Cell Carcinoma: Reducing Ionizing Radiation (
SUPERIOR
): A Randomized Trial
Intensity Modulated Radiotherapy
Radiotherapy
cancer therapy
Head and neck squamous cell carcinoma
Oropharyngeal squamous cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT06525220
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma (
MCLA-158-CL03
)
anti-PD-1 monoclonal antibody
bispecific EGFR/LGR5 antibody
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
NCT06515990
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors (
DM005001
)
bispecific-EGFR/cMET antibody-drug conjugate
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Solid tumour
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06496178
Advanced
Phase 3
Recruiting
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (
MCLA-158-CL02
)
bispecific EGFR/LGR5 antibody
Head and neck squamous cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06307015
Radonc
NA
Not yet recruiting
De-escalation of Radiation Dose in HPV-associated Oropharyngeal Squamous Cell Carcinoma Utilising FMISO PET and Magnetic Resonance Imaging as Non-Invasive Biomarkers of Hypoxia (
DE-RADIATE
)
Radiotherapy
cancer therapy
Oropharyngeal squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
NCT06305962
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06295731
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (
HexAgon-HN
)
anti-PD-1 monoclonal antibody
Head and neck squamous cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Breast cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06238479
Advanced
Phase 1
Recruiting
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors (
EXCEED
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06082167
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (
STELLAR-305
)
MET/VEGFR2/AXL/MER inhibitor
anti-PD-1 monoclonal antibody
Head and neck squamous cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06064877
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (
FIERCE-HN
)
anti-EGFR monoclonal antibody
anti-HGF monoclonal antibody
placebo
Head and neck squamous cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2217 - Kogarah - St George Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
STING agonist
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05706129
Radonc
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors (
Debio-0228-101
)
Bladder cancer
Clear cell renal cell carcinoma
Colorectal cancer
Head and neck cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
Triple-negative breast cancer
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05647122
Advanced
Phase 1
Recruiting
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors (
EGRET
)
anti EGFR/cMET antibody-drug conjugate
Head and neck squamous cell carcinoma
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05581004
Advanced
Phase 1
Recruiting
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (
GO43860
)
unknown drug class
Gastric cancer
Head and neck squamous cell carcinoma
Melanoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT05025813
Curative
Phase 2
Recruiting
A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab -
DESQUAMATE
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT04534205
Advanced
Phase 2 / Phase 3
Recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (
AHEAD-MERIT
)
anti-PD-1 monoclonal antibody
vaccine therapy,HPV-E6/HPV-E7-targeting
Head and neck cancer
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital (WITHDRAWN)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT03746431
Radonc
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours (
FPX-01-01
)
FPI-1175
FPI-1547
IGF1R-radionucleotide conjugate
cancer therapy
radioconjugate therapy
radiopharmaceutics
Breast cancer
Carcinoma
Cervical cancer
Endometrial cancer
HER2-negative breast cancer
Head and neck squamous cell carcinoma
Ovarian cancer
Solid tumour
Triple-negative breast cancer
Uveal melanoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
NCT02628067
Advanced
Phase 2
Recruiting
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) (
KEYNOTE-158
)
anti-PD-1 monoclonal antibody
Anal cancer
Biliary tract cancer
Cancer
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Endometrial cancer
Endometrial carcinoma
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Solid tumour
Thyroid cancer
Vulval cancer
ACTRN12622000495729
Radonc
Not Applicable
Recruiting
Stereotactic Ablative Radiotherapy and T Cell Biodistribution for Oligoprogressive Head and Neck Cancer (
START-HN
)
radiotherapy
Head and neck cancer
ACTRN12621001548820
Radonc
Not Applicable
Not yet recruiting
A Phase 2 study investigating the feasibility of stereotactic ablative body radiotherapy for the palliation of Head and Neck Cancer (
STEREOPHONIC
)
radiotherapy
Head and neck cancer
NSW
2170 - Liverpool - Liverpool Hospital
ACTRN12617001248358
Curative
Not yet recruiting
EPA and DHA as adjuvant therapy to improve outcome for patients with head and neck cancer undergoing chemoradiotherapy
Radiotherapy
cancer therapy
Head and neck cancer
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12615000771550
Radonc
Phase 2
Not yet recruiting
Effect of Adaptive Radiotherapy on the dose to Organs at Risk and Target Volumes in patients with Locally Advanced Head and Neck Cancer (
ART-Study
)
radiotherapy
Head and neck cancer
ACTRN12614000491662
Radonc
Phase 0
Not yet recruiting
For patients with advanced head and neck squamous cell carcinoma, does Cetuximab Radiolabelled with Gallium-68, Lutetium-177 or Rhenium-188 exhibit tumour uptake relative to background sufficiently to enable targeted radioimmunotherapy? (
The-ReCHANCE-Study
)
anti-EGFR monoclonal antibody
Head and neck squamous cell carcinoma
ACTRN12625000311459
Radonc
Not Applicable
Active not recruiting
Effect of Functional Imaging Guided Salivary Gland Sparing Radiation Therapy on Xerostomia Toxicity and Quality of Life in Adults with Primary Carcinoma of the Head and Neck Region. (
FIGS-RT
)
radiotherapy
Head and neck cancer
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (29)
Not yet recruiting (7)
Active not recruiting (1)
Status unknown (1)
Recruitment Country and State
NSW (25)
VIC (17)
QLD (13)
SA (11)
WA (9)
TAS (1)
NZ (1)
Phase
Phase 0 (1)
Phase 1 (13)
Phase 1 / Phase 2 (5)
Phase 2 (6)
Phase 2 / Phase 3 (4)
Phase 3 (3)
Trial Type
Advanced (25)
Radonc (10)
Curative (2)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
47%
PD-1
45%
EGFR
18%
MET
8%
LGR5
5%
PD-L1
5%
SIRPa
3%
prostaglandin DP1 receptor
3%
prostaglandin EP2 receptor
3%
prostaglandin EP4 receptor
3%
TIGIT
3%
B7H3
3%
Nectin-4
3%
ERBB3
3%
AXL
3%
MER
3%
VEGFR2
3%
HGF
3%
STING
3%
CD39
3%
VEGF
3%
IL-2
3%
CCR8
3%
TP53
3%
TP53 Y220C
3%
HPV-E6
3%
HPV-E7
3%
ALK
3%
ATR
3%
BCR-ABL1
3%
CDK4
3%
CDK6
3%
CRAF
3%
FLT3
3%
JAK1
3%
JAK2
3%
KIT
3%
PDGFR
3%
PDGFRA
3%
PI3K
3%
RAF
3%
ROS1
3%
SMO
3%
SRC
3%
VEGFR
3%
YES1
3%
mTOR
3%
mTORC1
3%
mTORC2
3%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (8)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (7)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
3168 - Clayton - Monash Medical Centre (4)
5042 - Bedford Park - Flinders Medical Centre (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
6009 - Nedlands - Linear Clinical Research (3)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (3)
2500 - Wollongong - Wollongong Hospital (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2217 - Kogarah - St George Hospital (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
2170 - Liverpool - Liverpool Hospital (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
6009 - Nedlands - One Clinical Research (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
6150 - Murdoch - GenesisCare Murdoch (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
4215 - Southport - Tasman Oncology (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2109 - North Ryde - Macquarie University Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
Cancer Type
Cancer
Head and neck cancer
Solid tumour
Head and neck squamous cell carcinoma
Thoracic cancer
Gastrointestinal cancer
Gynaecological cancer
Lung cancer
Respiratory tract cancer
HPV-related cancer
HPV16-positive cancer
Upper gastrointestinal cancer
Viral-related cancer
Breast cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Cervical cancer
Urogenital cancer
Breast adenocarcinoma
Triple-negative breast cancer
Bladder cancer
Colorectal cancer
Gastroesophageal cancer
Lower gastrointestinal cancer
Melanoma
Gastric cancer
Oesophageal cancer
Carcinoma
Endometrial cancer
Clear cell renal cell carcinoma
Kidney cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Male genital cancers
Prostate cancer
Skin cancer
Epithelial Ovarian Cancer
Hepatobiliary cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Hepatocellular carcinoma
Sarcoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Cutaneous squamous cell carcinoma
Non-melanoma skin cancer
Oropharyngeal squamous cell carcinoma
Cutaneous melanoma
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Prostate adenocarcinoma
Biliary tract cancer
Uveal melanoma
Squamous non-small-cell lung cancer
Urothelial carcinoma
Endometrial carcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Mesothelioma
HER2-negative breast cancer
Anal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Liposarcoma
Soft tissue sarcoma
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
Castrate-resistant prostate cancer
Platinum resistant ovarian cancer
Renal pelvis cancer
Oesophageal squamous cell carcinoma
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
Follicular lymphoma
Haematological malignancy
High-grade B-cell lymphoma
Lymphoma
Mantle cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Fallopian tube cancer
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Non-squamous non-small-cell lung cancer
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
dMMR solid cancer
Colorectal adenocarcinoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
HER2-positive breast cancer
Anal squamous cell carcinoma
Squamous cell carcinoma
Cholangiocarcinoma
Endocrine gland cancer
Gastro-entero-pancreatic neuroendocrine tumour
Lung carcinoid tumour
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Thyroid cancer
Vaginal and vulvar cancer
Vulval cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy